Stopped: FDA and Sponsor closed trial. New post-marketing approval trial in development.
PURPOSE: The primary purpose of this study is to demonstrate that the Composite Clinical Success of the study group receiving the SuperionĀ® IDS is not inferior to the success rate observed in the study group treated by direct decompression at 60 months follow-up. Secondarily, the trial is intended to establish that Composite Clinical Success of the study group receiving the SuperionĀ® IDS at 24 months is not inferior to the success rate observed at 24 months in patients treated with the SuperionĀ® IDS in the original IDE trial. Thirdly, the trial is intended to establish that Composite Clinical Success of the population receiving the SuperionĀ® IDS in this trial at 24 months is not inferior to the success rate observed at 24 months in patients treated with direct decompression.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Composite Endpoint (Primary)
Timeframe: 60 Months
Zurich Claudication Questionnaire (ZCQ)
Timeframe: 60 Months
No re-operations, revisions, removals, or supplemental fixation at the index level(s)
Timeframe: 60 Months
Epidural steroid injections for the treated level(s)
Timeframe: 60 Months